Last edition
News about "NATCO Pharma"
Breckenridge Launches Everolimus Tablets, 1mg, generic version of Zortress
Breckenridge Pharmaceutical has announced the launch of Everolimus Tablets, 1 mg, the generic equivalent of Zortress. An mTOR inhibitor immunosuppressant, Everolimus is indicated for the prevention of organ rejection in adult kidney and liver transplant patients and will be available through retail, mail-order pharmacies, and clinics.
Natco Pharma | 31/10/2025 | By Dineshwori
Natco Pharma to Acquire 35.75 Percent Stake in South Africa's Adcock Ingram, Delisting Planned
Natco Pharma has announced its intention to acquire a 35.75 percent equity stake in South Africa’s Adcock Ingram Holdings, in a deal valued at approximately INR 2,000 crore. This transaction is expected to make Natco the second-largest shareholder, while Bidvest will retain a 64.25 percent holding.
Natco Pharma | 13/10/2025 | By Darshana | 174
NATCO Pharma's Kothur Facility Receives FDA EIR with VAI Classification
The US Food and Drug Administration (FDA) has completed an inspection at NATCO Pharma’s Pharma division located in Kothur, Hyderabad, India.
NATCO Pharma | 18/09/2025 | By Dineshwori | 231
NATCO Launches Tracleer Generic in US with Lupin
NATCO Pharma has announced the launch of Bosentan tablets for oral suspension (TFOS), 32mg, a generic version of Tracleer by Actelion Pharmaceuticals US Inc., in partnership with Lupin.
NATCO Pharma | 20/08/2025 | By Dineshwori | 190
Bhimrao Jadhav Joins NATCO Pharma as Senior VP of Formulations Operations
Jadhav holds a Bachelor’s degree in Pharmacy and brings over 30 years of experience in pharmaceutical operations management.
NATCO Pharma | 05/03/2025 | By Aishwarya | 706
NATCO Pharma has secured approval for generic Everolimus tablets for oral suspension. The company’s marketing partner for the ANDA, Breckenridge Pharmaceutical plans to launch it in the US market immediately.
NATCO Pharma | 30/01/2025 | By Abha | 440
NATCO Pharma Announces Investment of USD 8 Million in eGenesis
The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.
NATCO Pharma | 04/09/2024 | By Aishwarya | 496
Natco Pharma Submits ANDA for Generic Version of TABRECTA
Natco claims to be the first company to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of the potential launch of the product under certain circumstances.
Natco Pharma | 31/08/2024 | By Aishwarya | 532
Natco Pharma | 24/04/2023 | By Sudeep Soparkar | 1200
NATCO launches additional strengths for generic version of Revlimid in US
The generic version of Revlimid (lenalidomide capsules) are of strengths in 2.5 mg, and 20 mg
NATCO Pharma | 11/03/2023 | By Sudeep Soparkar | 923
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy